FMS樣酪氨酸激酶3(Flt3)重組蛋白
Recombinant FMS Like Tyrosine Kinase 3 (Flt3)
CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2
- 編號URPA039Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位細(xì)胞膜, 內(nèi)質(zhì)網(wǎng)腔
- 預(yù)測分子量27.5kDa
- 實(shí)際分子量27kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Lys335~Ser544 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)8.3
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 550 ¥ 1374 ¥ 2748 ¥ 8244 ¥ 20610
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA039Mu01 | FMS樣酪氨酸激酶3(Flt3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA039Mu01 | FMS樣酪氨酸激酶3(Flt3)多克隆抗體 | WB |
| ULAA039Mu71 | FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Frontiers in physiology | Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303] |
| PLoS One | Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and?… [Pubmed: 30235245] |
| Bioscience Reports | N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858] |
| Molecular Neurobiology | Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic?… [Doi: 10.1007/s12035-017-0835-5] |
| Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
留言咨詢
